We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cigna (CI) Up 1.5% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for Cigna (CI - Free Report) . Shares have added about 1.5% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Cigna due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Cigna Earnings Surpass Estimates in Q2, Improve Y/Y
Cigna’s second-quarter 2020 earnings of $5.81 per share surpassed the Zacks Consensus Estimate by 15% and also grew 35% year over year.
Results reflected revenue and earnings growth owing to a strong fundamental performance and lower medical costs from deferred care following the COVID-19 pandemic.
Cigna’s revenues of $39.3 billion beat the Zacks Consensus Estimate by 4.2% and also increased 13.9% year over year mirroring solid contributions from each of the company's ongoing businesses.
The company’s medical enrollment grew by 86,000 lives from the prior-year quarter to 17.083 million customers, attributable to membership gains in the Government and International markets.
Selling, general and administrative expense ratio was 8.4, improved 60 basis points year over year on significant growth in revenues and cost-control measures.
Strong Segmental Performances
Health Services: Adjusted revenues of $28.6 billion were up 21.5% year over year, driven by insourcing of Integrated Medical pharmacy volumes and a sturdy performance in specialty pharmacy services, partly offset by a decline in retail script volumes.
Operating income of $1.25 billion increased 7% year over year, representing customer growth, higher adjusted pharmacy scripts volumes, benefits from effective management of the supply chain and a steady performance in specialty pharmacy services, partially offset by an increase in operating expenses to support growth
Integrated Medical: Adjusted revenues of $9.23 billion were up 3% year over year, highlighting customer wins in Medicare Advantage and in the Select segment, as well as premium growth. However, this upside was partially offset by premium relief programs for clients that were carried out in response to the COVID-19 pandemic.
Operating income of $1.52 billion surged 53.83% year over year on significantly lower medical utilization in both the Commercial and Government segments compared with the historic patterns. However, this uptrend was partially offset by premium relief programs for clients and cost share waivers for customers.
International Markets: Adjusted revenues of $1.43 billion were up 3.1% year over year, reflecting consistent business growth, partially offset by an adverse foreign currency movement.
Operating earnings of $319 million soared 54.1% year over year, driven by lower claim levels amid the COVID-19 pandemic, constant business gains and operational efficiency.
Group Disability and Other Operations: Adjusted revenues of $1.33 billion inched up 1.5% year over year. Operating earnings of $132 million were down 11.4% year over year due to elevated claims in Cigna’s Life business, primarily related to the COVID-19 pandemic. However, this downside was partially mitigated by a favorable performance within the Disability business.
Capital Position
Cigna’s debt-to-capitalization ratio improved to 43.5 as of Jun 30, 2020 from 45.2 as of Dec 31, 2019.
Shareholders’ equity as of Jun 30, 2020 was $47.4 billion, up 8.1% year over year.
Share Buyback
Year to date through Jul 29, 2020, the company repurchased 8.3 million shares of common stock for $1.5 billion.
2020 Guidance
The company’s earlier-issued guidance for the full year was intact, indicating earnings per share to remain in the range of $18-$18.6 while adjusted revenues in the $154-$156 billion band.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month. The consensus estimate has shifted -7.74% due to these changes.
VGM Scores
At this time, Cigna has a great Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Cigna has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cigna (CI) Up 1.5% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Cigna (CI - Free Report) . Shares have added about 1.5% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Cigna due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Cigna Earnings Surpass Estimates in Q2, Improve Y/Y
Cigna’s second-quarter 2020 earnings of $5.81 per share surpassed the Zacks Consensus Estimate by 15% and also grew 35% year over year.
Results reflected revenue and earnings growth owing to a strong fundamental performance and lower medical costs from deferred care following the COVID-19 pandemic.
Cigna’s revenues of $39.3 billion beat the Zacks Consensus Estimate by 4.2% and also increased 13.9% year over year mirroring solid contributions from each of the company's ongoing businesses.
The company’s medical enrollment grew by 86,000 lives from the prior-year quarter to 17.083 million customers, attributable to membership gains in the Government and International markets.
Selling, general and administrative expense ratio was 8.4, improved 60 basis points year over year on significant growth in revenues and cost-control measures.
Strong Segmental Performances
Health Services: Adjusted revenues of $28.6 billion were up 21.5% year over year, driven by insourcing of Integrated Medical pharmacy volumes and a sturdy performance in specialty pharmacy services, partly offset by a decline in retail script volumes.
Operating income of $1.25 billion increased 7% year over year, representing customer growth, higher adjusted pharmacy scripts volumes, benefits from effective management of the supply chain and a steady performance in specialty pharmacy services, partially offset by an increase in operating expenses to support growth
Integrated Medical: Adjusted revenues of $9.23 billion were up 3% year over year, highlighting customer wins in Medicare Advantage and in the Select segment, as well as premium growth. However, this upside was partially offset by premium relief programs for clients that were carried out in response to the COVID-19 pandemic.
Operating income of $1.52 billion surged 53.83% year over year on significantly lower medical utilization in both the Commercial and Government segments compared with the historic patterns. However, this uptrend was partially offset by premium relief programs for clients and cost share waivers for customers.
International Markets: Adjusted revenues of $1.43 billion were up 3.1% year over year, reflecting consistent business growth, partially offset by an adverse foreign currency movement.
Operating earnings of $319 million soared 54.1% year over year, driven by lower claim levels amid the COVID-19 pandemic, constant business gains and operational efficiency.
Group Disability and Other Operations: Adjusted revenues of $1.33 billion inched up 1.5% year over year. Operating earnings of $132 million were down 11.4% year over year due to elevated claims in Cigna’s Life business, primarily related to the COVID-19 pandemic. However, this downside was partially mitigated by a favorable performance within the Disability business.
Capital Position
Cigna’s debt-to-capitalization ratio improved to 43.5 as of Jun 30, 2020 from 45.2 as of Dec 31, 2019.
Shareholders’ equity as of Jun 30, 2020 was $47.4 billion, up 8.1% year over year.
Share Buyback
Year to date through Jul 29, 2020, the company repurchased 8.3 million shares of common stock for $1.5 billion.
2020 Guidance
The company’s earlier-issued guidance for the full year was intact, indicating earnings per share to remain in the range of $18-$18.6 while adjusted revenues in the $154-$156 billion band.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month. The consensus estimate has shifted -7.74% due to these changes.
VGM Scores
At this time, Cigna has a great Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Cigna has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.